TO THE EDITOR
=============

Spontaneous regression (SR) of malignant tumors has been observed in several types of tumors including lymphoma, kidney cancer, melanoma, and neuroblastoma.[@r1] SR is currently of interest for many clinicians because of an increased number of methotrexate-related lymphoproliferative disorders, and because SR is observed in many patients after withdrawal of methotrexate.[@r2] In terms of a mechanism, anti-tumor immune responses by host T lymphocytes reacting against tumor cells are believed to be involved in SR,[@r3] and several cases have recently been reported. In a recent issue of journal of clinical and experimental hematopathology (*JCEH*), Tanaka *et al*. described a case of diffuse large B-cell lymphoma (DLBCL) with SR.[@r4] A 35-year-old man had multiple mesenteric lymphadenopathy and a thickened small intestine wall, and was diagnosed with DLBCL (germinal center origin) without infection with Epstein-Barr virus (EBV) following laparoscopic lymph node biopsy. However, symptoms were improved and abnormal accumulation of fluorodeoxyglucose was disappeared 3 months after the biopsy. In addition, Abe *et al*. previously reported in *JCEH* a case of DLBCL harboring EBV infection with SR and reviewed some published SR cases of aggressive non-Hodgkin's lymphoma.[@r5] SR has also been seen in low-grade lymphoma. Matsuo *et al*. described a case of bilateral conjunctival extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue with SR.[@r6] Ye *et al*. just recently published four cases of SR in patients with mantle cell lymphoma.[@r7] SR is preferentially seen in extranodal lymphoma including in the intestinal tract.

SR (also referred as "healing") is also observed in patients with non-hematological malignant tumors such as lung cancer, kidney cancer, breast cancer, and melanoma.[@r8]^-^[@r11] These solid cancers are known as immunogenic tumors because of increased expression of neoantigens, and anti-tumor therapy using immune checkpoint blockade antibodies and cytokines such as interferons have been used for these cancers.[@r12]^,^[@r13] However, mutation burdens of high-grade lymphomas are less than those of melanoma and lung cancers, indicating that unknown mechanisms are involved in SR in lymphoma cases.[@r14]

CD80 and CD86 are well-known co-stimulatory molecules expressed on antigen-presenting cells including B cells. CD80 is expressed on lymphoma cells in 90% of DLBCL cases,[@r15] and the expression of both CD80 and CD86 is widely seen in leukemia or lymphoma cell lines in the NCI-60 cancer panel database \[GEO data set, GDS4296\]. As shown in [figure 1](#f1){ref-type="fig"}, CD80 expression was observed in B-cell lymphoma and B-cell lymphoma cell lines. In addition, human leukocyte antigen (HLA)-DR, one of major histocompatibility complex (MHC) class II molecules, is also expressed in 65% of DLBCL cases, and HLA-DR-positive cases show a significantly better clinical course.[@r16] Given that lymphoma cells in DLBCL expressing co-stimulatory molecules such as CD80/CD86 and MHC class II molecules, lymphoma cells may have the higher immunogenic potential than other solid tumors. In support of this, Allison (received the Nobel Prize in 2018) *et al*. previously found that ectopic expression of CD80 on tumor cells induces T cell-mediated rejection in murine models by not CD4-positive T cells but CD8-positive T cells.[@r17] In addition, clinical trials with tumor cell vaccines using CD80-transfected autologous or allogenic tumor cells were performed for kidney cancer, lung cancer, and acute myeloid leukemia.[@r18] As a result, some patients who enrolled in these trials showed significant tumor reduction.[@r19]^-^[@r21] Although the overall response rate was limited, these findings indicate that CD80-expressing tumor cells could enhance anti-tumor immune responses. The interaction between CD80/CD86 and CD28 activates tumor-specific T cells to produce interleukin (IL)-2, which in turn triggers T cell proliferation in autocrine and paracrine manners in tumor microenvironment ([Figure 2](#f2){ref-type="fig"}). Given that the interaction between CD80/86 and CTLA-4 results in T cell inactivation, therapies to block CTLA-4-mediated immunosuppression may improve this immune response.

![CD80 expression in lymphoma tissues and cell lines. (*A*) The immunostaining using anti-CD80 monoclonal antibody (clone EPR1157, Abcam) was performed as described previous methods.[@r30] Lymphoma cells were weakly positive for CD80 in diffuse large B-cell lymphoma (*A*), and strongly positive in two B-cell lymphoma cell lines (SLVL and BALL1) (*B*). Scale bar; 20μm.](jslrt-59-207-g001){#f1}

![Scheme of the suggested mechanisms of spontaneous regression (SR). (*A*) In the growing phase of lymphoma, lymphoma cells are protected from microenvironment that includes cytotoxic T lymphocytes. Stress or injury disrupts the microenvironment, and immune reactions between T lymphocytes and lymphoma cells can be initiated. (*B*) Co-stimulatory molecules such as CD80/CD86 stimulate lymphoma-specific T cell response. Activated T lymphocytes proliferate and attack lymphoma cells, which present neoantigens or viral antigens with HLA class I or class II molecules.](jslrt-59-207-g002){#f2}

Regarding EBV-infected lymphoma or lymphoproliferation, anti-EBV immune responses are believed to induce anti-lymphoma immune responses and SR.[@r22] However, EBV-transformed B lymphocytes and EBV-infected lymphoma cells produce IL-12, which is a cytokine to promote cellular immunity and is produced after CD40 ligation.[@r23] IL-12 production from lymphoma cells may be involved in SR in EBV-infected lymphoma or lymphoproliferative disorders.

Traumatic stress or injury including biopsy is considered to be a trigger for SR, and occasionally, administration of corticosteroids, anti-lymphoma drugs, or infection may cause the initiation of SR.[@r1]^-^[@r3] We propose a possibility that, after lymphoma cells are exposed to anti-lymphoma T lymphocytes by physical disruption of the microenvironment, immune reaction between lymphoma cells and lymphoma-specific T lymphocytes may be initiated. Damage-associated molecular patterns are also considered to be involved in this immune reaction by activating the STING pathway in antigen-presenting cells.[@r24]

Recent advances of immunotherapy indicated the significance of programmed death-1 (PD-1) and its ligands such as PD-L1 and PD-L2. PD-L1-expression in lymphoma cells was seen in 11% of cases and reportedly associated to poor clinical course in DLBCL.[@r25] PD-L1 expression in lymphoma cells were potentially mediated by Stat3 activation which were suggested to be induced by macrophage-derived factors.[@r26]^,^[@r27] Indoleamine 2,3-dioxygenase (IDO) which has immunosuppressive functions due to enzymatic activities catalyzing the essential amino acid L-tryptophan was also expressed on 32% of B-cell lymphoma cases and IDO expression was associated to poor outcome.[@r28] These immunosuppressive molecules are also expressed on myeloid cells such as tumor associated macrophages.[@r29] Down-regulation of these factors might be linked to SR in lymphoma cases.

In conclusion, the expression of CD80/CD86 on lymphoma cells is potentially associated with activation of anti-lymphoma T cell responses and clinical SR. HLA-DR expression on lymphoma cells may also influence activation of lymphoma-specific CD4-positive helper T cells in the microenvironment. As a therapeutic strategy, anti-CTLA-4 antibody rather than anti-PD-1/PD-L1 antibody may be helpful to enhance anti-lymphoma T cell response in cases of CD80/CD86-positive lymphoma.
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